Wire · opportunities
SimBioSys nabs FDA clearance for Nvidia-powered, MRI-derived breast cancer recurrence tool
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 October 2026 · Fusion42 review
SimBioSys received FDA clearance for TumorSight Risk, an AI-powered tool using MRI, pathology, and clinical data to predict breast cancer recurrence risk in HR-positive, HER2-negative early-stage patients, providing personalised prognostic insights within standard clinical workflows.
This Wire brief sits within Fusion42's coverage of Medtech, and 6 sources have reported it between 15 Oct 2026 and 17 Oct 2026.
◆ ◆ The Wire takeaway
You now have a tool that delivers personalised breast cancer recurrence risk within an hour using data you already collect. This accelerates patient decisions and opens a new way to compete by integrating AI with routine MRI workflows.
◆ Coverage
6 sources · first reported 15 Oct 2026 · latest 17 Oct 2026
◆ Related on Wire
◆ Topics